Paris, France

Nicolas Billiald

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Nicolas Billiald: Innovator in Immunotherapy

Introduction

Nicolas Billiald is a prominent inventor based in Paris, France. He has made significant contributions to the field of immunotherapy, particularly in the treatment of autoimmune and inflammatory disorders. His innovative approach combines interleukin-2 with an interleukin-1 inhibitor, showcasing his commitment to advancing medical science.

Latest Patents

Nicolas Billiald holds 1 patent for his invention titled "Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof." This patent relates to a combination of interleukin-2 (IL-2) and an interleukin-1 (IL-1) inhibitor, aimed at treating autoimmune and inflammatory disorders in subjects. The invention also includes a pharmaceutical composition comprising IL-2 and an IL-1 inhibitor, as well as a conjugate that features IL-2 conjugated to an IL-1 inhibitor.

Career Highlights

Throughout his career, Nicolas has worked with notable organizations such as Iltoo Pharma and Sorbonne Université. His work in these institutions has allowed him to collaborate with leading experts in the field, further enhancing his research and development efforts.

Collaborations

Nicolas Billiald has collaborated with esteemed colleagues, including David Klatzmann and Jérémie Mariau. These partnerships have contributed to the advancement of his research and the successful development of his patented innovations.

Conclusion

Nicolas Billiald is a key figure in the field of immunotherapy, with a focus on innovative treatments for autoimmune and inflammatory disorders. His contributions through patents and collaborations highlight his dedication to improving healthcare outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…